{"content":"<li class=\"n-box-item date-title\" data-end=\"1482555599\" data-start=\"1482469200\" data-txt=\"Sunday, December 22, 2019\">Friday, December 23, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3232475\" data-ts=\"1482532574\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232475-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li>\n<b>Top gainers, as of 5.25 p.m.:</b> <a href=\"https://seekingalpha.com/symbol/IONS\" title=\"Ionis Pharmaceuticals, Inc.\">IONS</a> <font color=\"green\">+6.5%</font>. <a href=\"https://seekingalpha.com/symbol/APLP\" title=\"Archrock Partners, L.P.\">APLP</a> <font color=\"green\">+1.6%</font>. <a href=\"https://seekingalpha.com/symbol/PVG\" title=\"Pretium Resources Inc\">PVG</a> <font color=\"green\">+1.5%</font>. <a href=\"https://seekingalpha.com/symbol/GIL\" title=\"Gildan Activewear Inc.\">GIL</a> <font color=\"green\">+1.0%</font>.</li>\n<li>\n<b>Top losers, as of 5.25p.m.:</b> <a href=\"https://seekingalpha.com/symbol/AVXS\" title=\"AveXis\">AVXS</a> <font color=\"red\">-8.1%</font>. <a href=\"https://seekingalpha.com/symbol/GERN\" title=\"Geron Corporation\">GERN</a> <font color=\"red\">-5.1%</font>. <a href=\"https://seekingalpha.com/symbol/CEMP\" title=\"Cempra, Inc.\">CEMP</a> <font color=\"red\">-3.2%</font>. <a href=\"https://seekingalpha.com/symbol/ARLZ-OLD\" title=\"Aralez Pharmaceuticals Inc.\">ARLZ-OLD</a> <font color=\"red\">-1.9%</font>. <a href=\"https://seekingalpha.com/symbol/ALKS\" title=\"Alkermes plc\">ALKS</a> <font color=\"red\">-1.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232475\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$IONS $APLP $PVG - After Hours Gainers / Losers https://seekingalpha.com/news/3232475-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3232475-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>748&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232471\" data-ts=\"1482530938\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JMEI\" target=\"_blank\">JMEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232471-jumei-reports-1h-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jumei reports 1H results</a></h4><ul>\n<li>Jumei (NYSE:<a href=\"https://seekingalpha.com/symbol/JMEI\" title=\"Jumei International Holding Limited\">JMEI</a>): 1H EPS of RMB0.94</li>\n<li>Revenue of RMB3.48B (+1.8% Y/Y)</li>\n<li>Shares <font color=\"green\">+3%</font> AH.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232471\" data-linked=\"Jumei reports 1H results\" data-tweet=\"$JMEI - Jumei reports 1H results https://seekingalpha.com/news/3232471-jumei-reports-1h-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3232471-jumei-reports-1h-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232467\" data-ts=\"1482529685\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232467-fda-oks-nusinersen-for-spinal-muscular-atrophy-ionis-pharma-up-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs nusinersen for spinal muscular atrophy; Ionis Pharma up 3% after hours</a></h4><ul>\n<li>The FDA approves Ionis Pharmaceuticals' (NASDAQ:<a href=\"https://seekingalpha.com/symbol/IONS\" title=\"Ionis Pharmaceuticals, Inc.\">IONS</a>) nusinersen, branded as Spinraza, for the treatment of children and adults with spinal muscular atrophy.</li>\n<li>Licensee Biogen (NASDAQ:<a href=\"https://seekingalpha.com/symbol/BIIB\" title=\"Biogen Inc.\">BIIB</a>) will market.</li>\n<li>IONS is ahead <font color=\"green\">3%</font> after hours on increased volume. BIIB is up <font color=\"green\">1%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232467\" data-linked=\"FDA OKs nusinersen for spinal muscular atrophy; Ionis Pharma up 3% after hours\" data-tweet=\"$IONS $IONS $BIIB - FDA OKs nusinersen for spinal muscular atrophy; Ionis Pharma up 3% after hours https://seekingalpha.com/news/3232467-fda-oks-nusinersen-for-spinal-muscular-atrophy-ionis-pharma-up-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3232467-fda-oks-nusinersen-for-spinal-muscular-atrophy-ionis-pharma-up-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232466\" data-ts=\"1482529005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232466-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li> <b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a> <font color='green'>+9.5%</font>. <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a> <font color='green'>+7.37%</font>. <a href='https://seekingalpha.com/symbol/AMJ' title='JPMorgan Alerian MLP Index ETN'>AMJ</a> <font color='green'>+4.06%</font>. <a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a> <font color='green'>+2.35%</font>. <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a> <font color='green'>+1.36%</font>.  </li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='red'>-5.7%</font>. <a href='https://seekingalpha.com/symbol/EWS' title='iShares MSCI Singapore Capped ETF'>EWS</a> <font color='red'>-5.52%</font>. <a href='https://seekingalpha.com/symbol/TAN' title='Guggenheim Solar ETF'>TAN</a> <font color='red'>-5.05%</font>. <a href='https://seekingalpha.com/symbol/FXI' title='iShares China Large-Cap ETF'>FXI</a> <font color='red'>-4.31%</font>. <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a> <font color='red'>-4.15%</font>. &nbsp; </li> </ul><div class=\"tiny-share-widget\" data-id=\"3232466\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$GAZ-OLD $UNG $AMJ - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3232466-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3232466-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232465\" data-ts=\"1482528895\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMY-OLD\" target=\"_blank\">IMMY-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232465-imprimis-pharma-secures-9_8m-private-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Imprimis Pharma secures $9.8M private capital raise</a></h4><ul>\n<li>Imprimis Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/IMMY-OLD\" title=\"Imprimis Pharmaceuticals, Inc.\">IMMY-OLD</a>) inks an agreement with investors, including certain board members, the CEO, CFO and Senior Director of Corporate Development, for the direct placement of 5.1M Units to raise ~$9.8M.</li>\n<li>Each Unit consists of one share of common stock and one three-year warrant to purchase one share of common at $1.79 at a combined price of $1.915.</li>\n<li>Net proceeds will fund its ophthalmology business and general corporate purposes.</li>\n<li>Today's close was $2.82 so investors should expect a down day on Tuesday.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232465\" data-linked=\"Imprimis Pharma secures $9.8M private capital raise\" data-tweet=\"$IMMY-OLD - Imprimis Pharma secures $9.8M private capital raise https://seekingalpha.com/news/3232465-imprimis-pharma-secures-9_8m-private-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3232465-imprimis-pharma-secures-9_8m-private-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232464\" data-ts=\"1482528109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APH\" target=\"_blank\">APH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232464-rbcs-top-big-tech-picks-for-2017-aapl-avgo-nvda-csco-txn\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC&#39;s top big tech picks for 2017: AAPL, AVGO, NVDA, CSCO, TXN</a></h4><ul>   <li>Apple (<a href=\"https://seekingalpha.com/symbol/AAPL\" title=\"Apple Inc.\">AAPL</a> <font color=\"green\">+0.2%</font>) is an unsurprising name among <a href=\"http://www.investors.com/news/technology/apple-broadcom-nvidia-among-rbcs-top-stock-picks-for-2017/\" target=\"_blank\">top tech picks for 2017</a> from RBC Capital Markets, and it joins Broadcom (<a href=\"https://seekingalpha.com/symbol/AVGO\" title=\"Broadcom Limited\">AVGO</a> <font color=\"green\">+0.7%</font>), Nvidia (<a href=\"https://seekingalpha.com/symbol/NVDA\" title=\"NVIDIA Corporation\">NVDA</a> <font color=\"green\">+2.5%</font>), Cisco Systems (<a href=\"https://seekingalpha.com/symbol/CSCO\" title=\"Cisco Systems, Inc.\">CSCO</a> <font color=\"green\">+0.2%</font>) and Texas Instruments (<a href=\"https://seekingalpha.com/symbol/TXN\" title=\"Texas Instruments Inc.\">TXN</a> <font color=\"green\">+0.2%</font>) among the firm's best large-cap bets.</li>    <li>Apple's likely to benefit from an iPhone 8 upgrade supercycle, say Amit Daryanani and Mitch Steves, and its services business is growing nicely. RBC's price target is $125, implying 7%-plus upside.</li>    <li>RBC named SMID picks as well: Amphenol (NYSE:<a href=\"https://seekingalpha.com/symbol/APH\" title=\"Amphenol Corporation\">APH</a>); Analog Devices (<a href=\"https://seekingalpha.com/symbol/ADI\" title=\"Analog Devices Inc.\">ADI</a> <font color=\"green\">+0.5%</font>); Arris International (<a href=\"https://seekingalpha.com/symbol/ARRS\" title=\"ARRIS International plc\">ARRS</a> <font color=\"red\">-1.3%</font>); CDW (<a href=\"https://seekingalpha.com/symbol/CDW\" title=\"CDW Corporation\">CDW</a> <font color=\"green\">+2%</font>); and Microsemi (<a href=\"https://seekingalpha.com/symbol/MSCC\" title=\"Microsemi Corporation\">MSCC</a> <font color=\"green\">+0.7%</font>).</li>    <li>Cisco (price target $35, 15% upside) will benefit from a few catalysts including its ongoing mix shift away from switching and routing, while Nvidia (price target $115, 5% upside) has the group's \"cleanest secular growth story.\"</li>    <li>Meanwhile, \"Trumponomics\" will help a number of tech companies in the coming year, the firm says. Repatriation of foreign profits should also give Apple a boost, as well as U.S. semiconductor companies.</li>    <li>\"Trumponomics should drive the narrative for 2017 given widespread implications for our coverage group,\" Daryanani and Steves say. \"Beyond that, we think fundamentals will enable a better revenue and margin narrative for most companies in 2017 with continued focus on M&amp;A.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232464\" data-linked=\"RBC&#39;s top big tech picks for 2017: AAPL, AVGO, NVDA, CSCO, TXN\" data-tweet=\"$APH $APH $AAPL - RBC&#39;s top big tech picks for 2017: AAPL, AVGO, NVDA, CSCO, TXN https://seekingalpha.com/news/3232464-rbcs-top-big-tech-picks-for-2017-aapl-avgo-nvda-csco-txn?source=tweet\" data-url=\"https://seekingalpha.com/news/3232464-rbcs-top-big-tech-picks-for-2017-aapl-avgo-nvda-csco-txn\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>66&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232455\" data-ts=\"1482523216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232455-technology-top-5-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SAJA' title='Sajan, Inc.'>SAJA</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/WTT' title='Wireless Telecom Group, Inc'>WTT</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CRNT' title='Ceragon Networks Ltd.'>CRNT</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CPSH' title='CPS Technologies Corp.'>CPSH</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/CYRN' title='CYREN Ltd.'>CYRN</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232455\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 pm\" data-tweet=\"$SAJA $QUIK $WTT - Technology - Top 5 Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3232455-technology-top-5-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3232455-technology-top-5-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232454\" data-ts=\"1482522796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CZR\" target=\"_blank\">CZR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232454-caesars-entertainment-higher-after-adjusting-reorganization-terms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caesars Entertainment higher after adjusting reorganization terms</a></h4><ul> <li>Caesars Entertainment (<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment'>CZR</a> <font color='green'>+6.3%</font>) trades higher after the casino operator amended some its reorganization terms.</li> <li>The casino operator changed some details on the debt that is set to go to senior lenders.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3232454\" data-linked=\"Caesars Entertainment higher after adjusting reorganization terms\" data-tweet=\"$CZR - Caesars Entertainment higher after adjusting reorganization terms https://seekingalpha.com/news/3232454-caesars-entertainment-higher-after-adjusting-reorganization-terms?source=tweet\" data-url=\"https://seekingalpha.com/news/3232454-caesars-entertainment-higher-after-adjusting-reorganization-terms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232453\" data-ts=\"1482521753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232453-portola-pharmaplus-20-betrixaban-nda-accepted-for-priority-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola Pharma +20% as betrixaban NDA accepted for priority review</a></h4><ul>\n<li>The application has been given a PDUFA date of June 24, 2017.</li>\n<li>Also, the European Medicines Agency has validated its MAA for betrixaban for extended-duration prophylaxis of VTE in adults with acute medical illness and risk factors for VTE. The EMA's CHMP is reviewing the application under a standard 210-day review period.</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/PTLA\" title=\"Portola Pharmaceuticals\">PTLA</a> <font color=\"green\">+19.7%</font>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232453\" data-linked=\"Portola Pharma +20% as betrixaban NDA accepted for priority review\" data-tweet=\"$PTLA - Portola Pharma +20% as betrixaban NDA accepted for priority review https://seekingalpha.com/news/3232453-portola-pharmaplus-20-betrixaban-nda-accepted-for-priority-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3232453-portola-pharmaplus-20-betrixaban-nda-accepted-for-priority-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232448\" data-ts=\"1482519615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232448-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PZE' title='Petrobras Argentina S.A.'>PZE</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/BIOA' title='BioAmber'>OTC:BIOA</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/GPL' title='Great Panther Silver Limited'>GPL</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='red'>-52%</font>. TVIA <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/GLF' title='GulfMark Offshore, Inc.'>GLF</a> <font color='red'>-9%</font>. PGH <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232448\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$PZE $BIOA $NAK - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3232448-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3232448-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232446\" data-ts=\"1482516984\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORBK\" target=\"_blank\">ORBK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232446-orbotech-perks-up-after-jefferies-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Orbotech perks up after Jefferies upgrade</a></h4><ul> <li>Orbotech (<a href=\"https://seekingalpha.com/symbol/ORBK\" title=\"Orbotech Ltd.\">ORBK</a> <font color=\"green\">+1.9%</font>) trades higher after Jefferies <a href=\"http://247wallst.com/investing/2016/12/23/top-analyst-upgrades-and-downgrades-fedex-gamestop-navistar-time-warner-ups-and-more/\" target=\"_blank\">upgrades</a> the tech stock to Buy from Neutral.</li> <li>Valuation is seen as attractive given the Israeli company's ability to bring new products to market quickly.</li> <li>The investment firm lifts its price target on Orbotech to $41.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3232446\" data-linked=\"Orbotech perks up after Jefferies upgrade\" data-tweet=\"$ORBK - Orbotech perks up after Jefferies upgrade https://seekingalpha.com/news/3232446-orbotech-perks-up-after-jefferies-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3232446-orbotech-perks-up-after-jefferies-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232445\" data-ts=\"1482516575\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232445-oil-rig-count-continues-to-climb\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil rig count continues to climb</a></h4><ul>\n<li>Work climbs again in the oil fields with Baker Hughes reporting the U.S. rig count up another 13 this week to 523.</li>\n<li>It's the 16th advance in 17 weeks.</li>\n<li>Crude today is <font color=\"red\">down marginally</font> to $52.83 per barrel.</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/USO\" title=\"The United States Oil ETF, LP\">USO</a>, however, is <font color=\"green\">ahead 0.45%</font>.</li>\n<li>ETFs: <a href=\"https://seekingalpha.com/symbol/USO\" title=\"The United States Oil ETF, LP\">USO</a>, <a href=\"https://seekingalpha.com/symbol/OIL\" title=\"iPath S&amp;P Crude Oil Total Return Index ETN\">OIL</a>, <a href=\"https://seekingalpha.com/symbol/UWT\" title=\"VelocityShares 3X Long Crude ETN\">UWT</a>, <a href=\"https://seekingalpha.com/symbol/UCO\" title=\"ProShares Ultra Bloomberg Crude Oil ETF\">UCO</a>, <a href=\"https://seekingalpha.com/symbol/DWT\" title=\"VelocityShares 3x Inverse Crude Oil ETN\">DWT</a>, <a href=\"https://seekingalpha.com/symbol/SCO\" title=\"ProShares UltraShort Bloomberg Crude Oil ETF\">SCO</a>, <a href=\"https://seekingalpha.com/symbol/BNO\" title=\"The United States Brent Oil ETF, LP\">BNO</a>, <a href=\"https://seekingalpha.com/symbol/DBO\" title=\"PowerShares DB Oil ETF\">DBO</a>, <a href=\"https://seekingalpha.com/symbol/DTO\" title=\"DB Crude Oil Double Short ETN\">DTO</a>, <a href=\"https://seekingalpha.com/symbol/UGA\" title=\"The United States Gasoline ETF, LP\">UGA</a>, <a href=\"https://seekingalpha.com/symbol/USL\" title=\"The United States 12 Month Oil ETF, LP\">USL</a>, <a href=\"https://seekingalpha.com/symbol/DNO\" title=\"The United States Short Oil ETF, LP\">DNO</a>, <a href=\"https://seekingalpha.com/symbol/OLO\" title=\"DB Crude Oil Long ETN\">OLO</a>, <a href=\"https://seekingalpha.com/symbol/UHN\" title=\"The United States Diesel-Heating Oil ETF, LP\">UHN</a>, <a href=\"https://seekingalpha.com/symbol/SZO\" title=\"DB Crude Oil Short ETN\">SZO</a>, <a href=\"https://seekingalpha.com/symbol/OLEM\" title=\"iPath Pure Beta Crude Oil ETN\">OLEM</a>, <a href=\"https://seekingalpha.com/symbol/OILK\" title=\"ProShares K-1 Free Crude Oil Strategy ETF\">OILK</a>, <a href=\"https://seekingalpha.com/symbol/OILX\" title=\"Etracs S&amp;P GSCI Crude Oil Total Return Index ETN\">OILX</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232445\" data-linked=\"Oil rig count continues to climb\" data-tweet=\"$USO $OIL $UWT - Oil rig count continues to climb https://seekingalpha.com/news/3232445-oil-rig-count-continues-to-climb?source=tweet\" data-url=\"https://seekingalpha.com/news/3232445-oil-rig-count-continues-to-climb\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232442\" data-ts=\"1482516012\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232442-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/OSBC' title='Old Second Bancorp, Inc.'>OSBC</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/CFBK' title='Central Federal Corporation'>CFBK</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232442\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$GROW $OSBC $CFBK - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3232442-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3232442-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232441\" data-ts=\"1482515861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232441-sears-revisits-2003-level\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears revisits 2003 level</a></h4><ul><li>Sears Holdings (SHLD) slides to its lowest level since 2003, with shares bottoming out at $8.71.</li><li>The drop in Sears today arrives amid a mixed day overall for department store stocks.</li><li>Last quarter, comparable sales fell 10% for Sears in the U.S., dampening confidence that the chain could turn in a strong holiday period performance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3232441\" data-linked=\"Sears revisits 2003 level\" data-tweet=\"$SHLDQ - Sears revisits 2003 level https://seekingalpha.com/news/3232441-sears-revisits-2003-level?source=tweet\" data-url=\"https://seekingalpha.com/news/3232441-sears-revisits-2003-level\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>278&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232438\" data-ts=\"1482515469\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVCN\" target=\"_blank\">NVCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232438-neovasc-wins-reprieve-on-91m-patent-payment-to-cardiaq-still-to-deposit-70m-in-escrow-account\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neovasc wins reprieve on $91M patent payment to CardiAQ, but still has to deposit $70M in escrow account; shares up 2%</a></h4><ul>\n<li>A Massachusetts district court grants Neovasc's (<a href=\"https://seekingalpha.com/symbol/NVCN\" title=\"Neovasc Inc.\">NVCN</a> <font color=\"green\">+1.8%</font>) request for stay of judgement preventing CardiAQ from collecting $91M in damages stemming from their patent dispute involving the Tiara valve replacement device. The court order will be in effect until Neovasc's appeal is completed.</li>\n<li>The company did not escape the financial overhang entirely, though. Under the terms of the stay, it agreed to deposit $70M into a joint escrow account and enter into a general security agreement related to the remaining damages. It will also need court approval for transactions outside of its normal course of business until its appeal is adjudicated or it deposits the rest of the money into escrow.</li>\n<li>The appeal process will take a year or more to complete.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3219128-neovasc-gets-thumped-patent-case-hook-91m-shares-plummet-41-percent\" target=\"_blank\">Neovasc gets thumped in patent case, on the hook for $91M; shares plummet 41%</a> (Nov. 1)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232438\" data-linked=\"Neovasc wins reprieve on $91M patent payment to CardiAQ, but still has to deposit $70M in escrow account; shares up 2%\" data-tweet=\"$NVCN - Neovasc wins reprieve on $91M patent payment to CardiAQ, but still has to deposit $70M in escrow account; shares up 2% https://seekingalpha.com/news/3232438-neovasc-wins-reprieve-on-91m-patent-payment-to-cardiaq-still-to-deposit-70m-in-escrow-account?source=tweet\" data-url=\"https://seekingalpha.com/news/3232438-neovasc-wins-reprieve-on-91m-patent-payment-to-cardiaq-still-to-deposit-70m-in-escrow-account\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232439\" data-ts=\"1482514988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232439-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/DPRX\" title=\"Dipexium Pharmaceuticals, LLC\">DPRX</a> <font color=\"green\">+28%</font>. <a href=\"https://seekingalpha.com/symbol/ACST\" title=\"Acasti Pharma, Inc.\">ACST</a> <font color=\"green\">+24%</font>. <a href=\"https://seekingalpha.com/symbol/MBRX\" title=\"Moleculin Biotech, Inc.\">MBRX</a> <font color=\"green\">+23%</font>. <a href=\"https://seekingalpha.com/symbol/PZE\" title=\"Petrobras Argentina S.A.\">PZE</a> <font color=\"green\">+20%</font>. <a href=\"https://seekingalpha.com/symbol/BIOA\" title=\"BioAmber\">OTC:BIOA</a> <font color=\"green\">+15%</font>. <a href=\"https://seekingalpha.com/symbol/CNAT\" title=\"Conatus Pharmaceuticals\">CNAT</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/RAVE\" title=\"RAVE Restaurant Group, Inc.\">RAVE</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/LIME-OLD\" title=\"lime energy co.\">LIME</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/NAK\" title=\"Northern Dynasty Minerals Ltd\">NAK</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/APTO\" title=\"Aptose Biosciences Inc.\">APTO</a> <font color=\"green\">+13%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/BCEI\" title=\"Bonanza Creek Energy\">BCEI</a> <font color=\"red\">-53%</font>. <a href=\"https://seekingalpha.com/symbol/SBBP\" title=\"Strongbridge Biopharma\">SBBP</a> <font color=\"red\">-18%</font>. <a href=\"https://seekingalpha.com/symbol/PZRX\" title=\"PhaseRx\">PZRX</a> <font color=\"red\">-13%</font>. <a href=\"https://seekingalpha.com/symbol/PSIX\" title=\"Power Solutions International, Inc.\">OTCPK:PSIX</a> <font color=\"red\">-12%</font>. TKAI <font color=\"red\">-12%</font>. <a href=\"https://seekingalpha.com/symbol/GLF\" title=\"GulfMark Offshore, Inc.\">GLF</a> <font color=\"red\">-12%</font>. TVIA <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/GNC\" title=\"GNC Holdings, Inc.\">GNC</a> <font color=\"red\">-11%</font>. OPXA <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/PHMD\" title=\"PhotoMedex, Inc.\">PHMD</a> <font color=\"red\">-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232439\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$DPRX $ACST $MBRX - Midday Gainers / Losers https://seekingalpha.com/news/3232439-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3232439-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232436\" data-ts=\"1482514189\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAH\" target=\"_blank\">CAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232436-cardinal-health-settles-civil-penalty-portion-of-dea-case-for-44m-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cardinal Health settles civil penalty portion of DEA case for $44M; shares up 1%</a></h4><ul>\n<li>Drug wholesaler Cardinal Health (<a href=\"https://seekingalpha.com/symbol/CAH\" title=\"Cardinal Health Inc.\">CAH</a> <font color=\"green\">+1.2%</font>) settles the outstanding civil penalty portion of its 2012 administrative settlement with the U.S. Drug Enforcement Agency (DEA) by agreeing to pay $44M. The U.S. Department of Justice and a number of state attorney generals have agreed to take no further action in the matter.</li>\n<li>The <a href=\"http://www.wsj.com/articles/SB10001424052702304371504577405920610240932\" target=\"_blank\">investigation </a>pertained to alleged large shipments of addictive pain pills in Florida. Its Lakeland, FL facility was suspended for two years from distributing controlled substances as a result.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232436\" data-linked=\"Cardinal Health settles civil penalty portion of DEA case for $44M; shares up 1%\" data-tweet=\"$CAH - Cardinal Health settles civil penalty portion of DEA case for $44M; shares up 1% https://seekingalpha.com/news/3232436-cardinal-health-settles-civil-penalty-portion-of-dea-case-for-44m-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3232436-cardinal-health-settles-civil-penalty-portion-of-dea-case-for-44m-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232435\" data-ts=\"1482514106\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DB\" target=\"_blank\">DB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232435-deutsche-reassures-staff-after-7_2-mortgage-settlement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche reassures staff after $7.2 mortgage settlement</a></h4><ul>\n<li>\"We are removing a long-standing uncertainty from Deutsche Bank (NYSE:<a href=\"https://seekingalpha.com/symbol/DB\" title=\"Deutsche Bank AG\">DB</a>),\" <a href=\"https://www.bloomberg.com/news/articles/2016-12-23/deutsche-bank-reassures-staff-of-strength-after-u-s-settlement\" target=\"_blank\">says a memo to employees</a>. \u201cWe anticipated that the credit market will welcome the sentiment. We anticipate paying coupons on all of our instruments on time and in full.\u201d</li>\n<li>Checking those credit markets, the cost of insuring Deutsche's subordinated bonds fell 31 basis points today to 352 bps - the lowest since June 1.</li>\n<li>Reportedly a sizable creditor to the incoming president, the bank says it isn't expecting favorable treatment once he assumes office.</li>\n<li>Turning to Russia, the memo says there is no indication of a breach in sanctions, but an internal probe did turn up \"deficiencies\" in the bank's systems and controls which are being addressed.</li>\n<li>The stocks has given back early post-settlement gains, and is now <font color=\"red\">down 0.3% </font>on the session.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3232334-deutsche-bank-settles-u-s-mortgage-case-7_2b\" target=\"_blank\">Deutsche Bank settles U.S. mortgage case for $7.2B</a> (Dec. 22)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232435\" data-linked=\"Deutsche reassures staff after $7.2 mortgage settlement\" data-tweet=\"$DB - Deutsche reassures staff after $7.2 mortgage settlement https://seekingalpha.com/news/3232435-deutsche-reassures-staff-after-7_2-mortgage-settlement?source=tweet\" data-url=\"https://seekingalpha.com/news/3232435-deutsche-reassures-staff-after-7_2-mortgage-settlement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232434\" data-ts=\"1482513119\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERIC\" target=\"_blank\">ERIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232434-ericsson-cisco-partnership-targeting-enterprise-public-clients\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ericsson/Cisco partnership targeting enterprise, public clients</a></h4><ul>   <li>Ericsson (<a href=\"https://seekingalpha.com/symbol/ERIC\" title=\"LM Ericsson Telephone Company\">ERIC</a> <font color=\"green\">+1.6%</font>) and Cisco Systems (<a href=\"https://seekingalpha.com/symbol/CSCO\" title=\"Cisco Systems, Inc.\">CSCO</a> <font color=\"green\">+0.3%</font>) will tighten their partnership in 2017 by aiming for <a href=\"http://www.reuters.com/article/us-ericsson-cisco-systems-idUSKBN14C1K2\" target=\"_blank\">new corporate and public clients</a>, says Ericsson's Rima Qureshi.</li>    <li>Qureshi, Ericsson's North American chief, says the two have been focused on telecom but will push harder for enterprise and public-sector customers ahead -- and Ericsson's forecasting receiving up to 25% of revenue outside the telecom operators sector by 2020.</li>    <li>\"We are investigating what we can do together within Industry &amp; Society, IoT (Internet of Things), smart cities and we're going to target specific public sector segments, specifically for example transportation, utilities ... And then of course we're looking at other segments such as security,\" she says.</li>    <li>Nothing's changed in the partnership's broad target: an extra $1B each in revenues by 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232434\" data-linked=\"Ericsson/Cisco partnership targeting enterprise, public clients\" data-tweet=\"$ERIC $ERIC $CSCO - Ericsson/Cisco partnership targeting enterprise, public clients https://seekingalpha.com/news/3232434-ericsson-cisco-partnership-targeting-enterprise-public-clients?source=tweet\" data-url=\"https://seekingalpha.com/news/3232434-ericsson-cisco-partnership-targeting-enterprise-public-clients\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232432\" data-ts=\"1482512419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232432-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CALM' title='Cal-Maine Foods, Inc.'>CALM</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TPB' title='Turning Point Brands'>TPB</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232432\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$OTIV $CALM $TPB - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3232432-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3232432-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232430\" data-ts=\"1482512219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLNK\" target=\"_blank\">NLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232430-mercks-ebola-vaccine-candidate-shows-encouraging-effect-in-guinea-based-study-licensor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merck&#39;s Ebola vaccine candidate shows encouraging effect in Guinea-based study; licensor NewLink Genetics up 8%</a></h4><ul>\n<li>Thinly traded micro cap NewLink Genetics (<a href=\"https://seekingalpha.com/symbol/NLNK\" title=\"NewLink Genetics Corporation\">NLNK</a> <font color=\"green\">+8%</font>) perks up on increased volume in response to a <a href=\"https://www.bloomberg.com/news/articles/2016-12-23/ebola-vaccine-made-by-merck-protects-against-deadly-virus\" target=\"_blank\">Bloomberg report</a> that its experimental Ebola vaccine, rVSV-ZEBOV, licensed to Merck (<a href=\"https://seekingalpha.com/symbol/MRK\" title=\"Merck &amp; Co Inc.\">MRK</a> <font color=\"green\">+0.2%</font>) in 2014, showed promising efficacy in an 11,000-person study in Guinea. The results were just <a href=\"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2816%2932621-6/fulltext\" target=\"_blank\">published</a> in <em>The Lancet</em>.</li>\n<li>Of the people who received the vaccine (one shot) in the final stage of the trial, no cases of Ebola were recorded after a 10-day incubation period. An earlier study showed rVSV-ZEBOV to be 100% effective in people who were in close contact with Ebola patients in Guinea.</li>\n<li>The vaccine candidate has Breakthrough Therapy status in the U.S. which is designed to accelerate the regulatory review process.</li>\n<li>The Ebola outbreak from 2013 - 2016 in West Africa claimed 11,300 lives before exhausting itself.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232430\" data-linked=\"Merck&#39;s Ebola vaccine candidate shows encouraging effect in Guinea-based study; licensor NewLink Genetics up 8%\" data-tweet=\"$NLNK $NLNK $MRK - Merck&#39;s Ebola vaccine candidate shows encouraging effect in Guinea-based study; licensor NewLink Genetics up 8% https://seekingalpha.com/news/3232430-mercks-ebola-vaccine-candidate-shows-encouraging-effect-in-guinea-based-study-licensor?source=tweet\" data-url=\"https://seekingalpha.com/news/3232430-mercks-ebola-vaccine-candidate-shows-encouraging-effect-in-guinea-based-study-licensor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232428\" data-ts=\"1482511188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYGN\" target=\"_blank\">MYGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232428-myriad-genetics-facing-loss-of-medicare-reimbursement-for-ra-test-vectra-da-shares-slump-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myriad Genetics facing loss of Medicare reimbursement for RA test Vectra DA; shares slump 7%</a></h4><ul>\n<li>Myriad Genetics (<a href=\"https://seekingalpha.com/symbol/MYGN\" title=\"Myriad Genetics, Inc.\">MYGN</a> <font color=\"red\">-6.5%</font>) is down on average volume in response to the Medicare claims processor Palmetto's <a href=\"http://www.streetinsider.com/Corporate+News/Myriad+Genetics+%28MYGN%29+Disappointed+that+the+MolDx+Program+Published+a+Draft+Non-Coverage+Decision+for+Vectra+DA+/12370402.html\" target=\"_blank\">proposed non-coverage </a>of the company's rheumatoid arthritis (RA) test <a href=\"https://vectrada.com/\" target=\"_blank\">Vectra DA</a> in its MolDx program, a development that could eliminate a good bit of the product's sales.</li>\n<li>Palmetto based its preliminary decision on a study called AMPLE which apparently undermined the test's credibility. Unsurprisingly, the company takes issue with the study's conclusions citing investigators' \"unconventional\" statistical method. It adds that the efficacy of Vectra DA has been demonstrated in more than 20 studies involving more than 3,000 patients.</li>\n<li>Palmetto's decsion is not final and there have been cases where non-coverage decisions have been rescinded. The company will, no doubt, discuss the recent addition of Vectra DA to United Rheumatology's  (a leading professional organization for rheumatologists) practice guidelines for adults with RA.</li>\n<li>See <a href=\"http://www.streetinsider.com/Corporate+News/Myriad+Genetics+%28MYGN%29+Disappointed+that+the+MolDx+Program+Published+a+Draft+Non-Coverage+Decision+for+Vectra+DA+/12370402.html\" target=\"_blank\">StreetInsider</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232428\" data-linked=\"Myriad Genetics facing loss of Medicare reimbursement for RA test Vectra DA; shares slump 7%\" data-tweet=\"$MYGN - Myriad Genetics facing loss of Medicare reimbursement for RA test Vectra DA; shares slump 7% https://seekingalpha.com/news/3232428-myriad-genetics-facing-loss-of-medicare-reimbursement-for-ra-test-vectra-da-shares-slump-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3232428-myriad-genetics-facing-loss-of-medicare-reimbursement-for-ra-test-vectra-da-shares-slump-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232426\" data-ts=\"1482509073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENPH\" target=\"_blank\">ENPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232426-enphaseminus-7-on-capital-raise-plans\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enphase -7% on capital raise plans</a></h4><ul><li>Enphase Energy (<a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='red'>-7.3%</font>) has initiated <a href=\"https://seekingalpha.com/filing/3334378\" target=\"_blank\">an At The Market agreement</a> with FBR to sell up to $17M in common stock from time to time.</li></ul><div class=\"tiny-share-widget\" data-id=\"3232426\" data-linked=\"Enphase -7% on capital raise plans\" data-tweet=\"$ENPH - Enphase -7% on capital raise plans https://seekingalpha.com/news/3232426-enphaseminus-7-on-capital-raise-plans?source=tweet\" data-url=\"https://seekingalpha.com/news/3232426-enphaseminus-7-on-capital-raise-plans\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232424\" data-ts=\"1482508840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SKX\" target=\"_blank\">SKX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232424-skechers-rallies-after-monness-crespi-turns-positive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skechers rallies after Monness Crespi turns positive</a></h4><ul> <li>Skechers (<a href=\"https://seekingalpha.com/symbol/SKX\" title=\"Skechers USA Inc.\">SKX</a> <font color=\"green\">+2.7%</font>) trades higher after Monness Crespi upgrades shares to a <a href=\"https://www.marketbeat.com/stocks/NYSE/SKX/\" target=\"_blank\">Buy rating</a> after being slotted previously at Neutral.</li> <li>The investment firm assigns a price target of $30 to the footwear stock.</li> <li>Shares of Skechers picked up momentum in late Novemer on renewed confidence that Q4 numbers from the company will please investors, although they still sit 39% below their lofty 52-week high of $34.27.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3232424\" data-linked=\"Skechers rallies after Monness Crespi turns positive\" data-tweet=\"$SKX - Skechers rallies after Monness Crespi turns positive https://seekingalpha.com/news/3232424-skechers-rallies-after-monness-crespi-turns-positive?source=tweet\" data-url=\"https://seekingalpha.com/news/3232424-skechers-rallies-after-monness-crespi-turns-positive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232405\" data-ts=\"1482508814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232405-healthcare-top-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top Gainers / Losers as of 11:00 am</a></h4><ul>     <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/DPRX\" title=\"Dipexium Pharmaceuticals, LLC\">DPRX</a> <font color=\"green\">+34%</font>. <a href=\"https://seekingalpha.com/symbol/ACST\" title=\"Acasti Pharma, Inc.\">ACST</a> <font color=\"green\">+30%</font>. <a href=\"https://seekingalpha.com/symbol/CNAT\" title=\"Conatus Pharmaceuticals\">CNAT</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/MBRX\" title=\"Moleculin Biotech, Inc.\">MBRX</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/TRIL\" title=\"Trillium Therapeutics Inc.\">TRIL</a> <font color=\"green\">+10%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/SBBP\" title=\"Strongbridge Biopharma\">SBBP</a> <font color=\"red\">-17%</font>. <a href=\"https://seekingalpha.com/symbol/PZRX\" title=\"PhaseRx\">PZRX</a> <font color=\"red\">-11%</font>. TKAI <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/PHMD\" title=\"PhotoMedex, Inc.\">PHMD</a> <font color=\"red\">-8%</font>. OPXA <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232405\" data-linked=\"Healthcare - Top Gainers / Losers as of 11:00 am\" data-tweet=\"$DPRX $ACST $CNAT - Healthcare - Top Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3232405-healthcare-top-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3232405-healthcare-top-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232422\" data-ts=\"1482508791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSAT\" target=\"_blank\">GSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232422-globalstar-moves-up-again-ahead-of-confirmed-tlps-approval\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globalstar moves up again ahead of confirmed TLPS approval</a></h4><ul>   <li>Globalstar (NYSEMKT:<a href=\"https://seekingalpha.com/symbol/GSAT\" title=\"Globalstar, Inc.\">GSAT</a>), which <font color=\"green\">moved up more than 22%</font> yesterday on reports of a positive FCC outcome for its proposed wireless service, <font color=\"green\">rose another 5.5%</font> premarket ahead of confirmation that the agency has <a href=\"https://apps.fcc.gov/edocs_public/attachmatch/DOC-342780A1.pdf\" target=\"_blank\">approved the technology</a>.</li>    <li>Shares are currently halted.</li>    <li>The FCC adopted Globalstar's report and order on Terrestrial Low-Power Service, which uses MSS spectrum, after it reportedly got the necessary three votes from Republican commissioners Ajit Pai and Mike O'Rielly along with Chairman Tom Wheeler.</li>\n<li>\n<strong>Updated:</strong> Back up and trading off the halt, shares are <font color=\"green\">up 5.8%</font> at 11:43 a.m.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3232205-globalstar-plus-20_4-percent-report-tlps-needed-fcc-votes\" target=\"_blank\">Globalstar +20.4% on report TLPS has needed FCC votes</a> (Dec. 22 2016)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232422\" data-linked=\"Globalstar moves up again ahead of confirmed TLPS approval\" data-tweet=\"$GSAT - Globalstar moves up again ahead of confirmed TLPS approval https://seekingalpha.com/news/3232422-globalstar-moves-up-again-ahead-of-confirmed-tlps-approval?source=tweet\" data-url=\"https://seekingalpha.com/news/3232422-globalstar-moves-up-again-ahead-of-confirmed-tlps-approval\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232413\" data-ts=\"1482506498\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACST\" target=\"_blank\">ACST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232413-acasti-pharma-up-big-second-time-in-month-shares-ahead-32\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acasti Pharma up big second time in a month; shares ahead 32%</a></h4><ul>\n<li>Thinly traded nano cap Acasti Pharma (<a href=\"https://seekingalpha.com/symbol/ACST\" title=\"Acasti Pharma, Inc.\">ACST</a> <font color=\"green\">+31.9%</font>) heads north on a healthy 30x surge in volume. The unusual action is the second recent spike. On November 29, shares popped almost 80% on turnover of 2.6M before round tripping.</li>\n<li>No particular news accounts for the action. The major looming event is the possible FDA OK of an abbreviated approval pathway for lead product candidate CaPre for the treatment of severe hypertriglyceridemia. The company successfully completed a bridging study with Glaxo's (<a href=\"https://seekingalpha.com/symbol/GSK\" title=\"GlaxoSmithKline\">GSK</a> <font color=\"green\">+0.2%</font>) LOVAZA (omega-3-acid ethyl esters) in September which will support its application to use the FDA's 505(b)(2) pathway, allowing some of the supporting data to be generated in studies performed by others.</li>\n<li>\n<a href=\"http://www.acastipharma.com/capre/\" target=\"_blank\">CaPre</a> is a highly concentrated omega-3 phospholipid, principally EPA and DHA, derived from krill. Acasti says it is absorbed more readily into the body than LOVAZA because the EPA and DHA are naturally free or bound to phospholipids instead of being \"esterified.\"</li>\n<li>Experienced biotech investors know the risks with tiny companies with modest floats, however, as evidenced by the round trip from the first spike.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3208711-acasti-pharma-advances-high-triglyceride-fighter-capre-bridging-study-shows-similar-safety\" target=\"_blank\">Acasti Pharma advances high triglyceride fighter CaPre, bridging study shows similar safety profile to Glaxo's Lovaza</a> (Sept. 14)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232413\" data-linked=\"Acasti Pharma up big second time in a month; shares ahead 32%\" data-tweet=\"$ACST $ACST $GSK - Acasti Pharma up big second time in a month; shares ahead 32% https://seekingalpha.com/news/3232413-acasti-pharma-up-big-second-time-in-month-shares-ahead-32?source=tweet\" data-url=\"https://seekingalpha.com/news/3232413-acasti-pharma-up-big-second-time-in-month-shares-ahead-32\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232414\" data-ts=\"1482505958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNC\" target=\"_blank\">GNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232414-piper-jaffray-warns-on-gnc-holdings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray warns on GNC Holdings</a></h4><ul> <li>Shares of GNC Holdings (<a href=\"https://seekingalpha.com/symbol/GNC\" title=\"GNC Holdings, Inc.\">GNC</a> <font color=\"red\">-7.4%</font>) trail off after Piper Jaffrey warns that Q4 consensus estimates are too high.</li> <li>GNC's price cuts and the elimination of paid memberships add to the risk of an earnings shortfall, says analyst Sean Naughton.</li> <li>PJ cuts its price target on Underweight-rated GNC to $7 from $11.</li>\n<li>Sources: Bloomberg and Marketbeat.com</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3232414\" data-linked=\"Piper Jaffray warns on GNC Holdings\" data-tweet=\"$GNC - Piper Jaffray warns on GNC Holdings https://seekingalpha.com/news/3232414-piper-jaffray-warns-on-gnc-holdings?source=tweet\" data-url=\"https://seekingalpha.com/news/3232414-piper-jaffray-warns-on-gnc-holdings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232408\" data-ts=\"1482505230\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTW\" target=\"_blank\">WTW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232408-sa-author-runs-circles-around-wall-street-on-weight-watchers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SA author runs circles around Wall Street on Weight Watchers</a></h4><ul> <li>Weight Watchers (NYSE:<a href=\"https://seekingalpha.com/symbol/WTW\" title=\"Weight Watchers International, Inc.\">WTW</a>) is <font color=\"green\">up 2.89%</font> to $11.40 as Oprah Winfrey's new TV spots and 40-lb weight drop stay in focus.</li> <li>Investment firms haven't made any ratings revisions since the Oprah news hit (?) - including Morgan Stanley which issued a poorly-timed downgrade last week (Underweight/$8 PT) - but SA contributor Courage &amp; Conviction Investing has some penetrating <a href=\"https://seekingalpha.com/article/4032217-time-epic-short-squeeze-weight-watchers\" target=\"_blank\">WTW analysis</a> (hint: \"epic short squeeze\").</li> <li>Shares of WTW traded as high as $12.45 yesterday off the Oprah buzz.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3232188-weight-watchers-soars-oprah-drops-40-lbs\" target=\"_blank\">Weight Watchers soars after Oprah drops 40 lbs</a> (Dec. 22)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3232408\" data-linked=\"SA author runs circles around Wall Street on Weight Watchers\" data-tweet=\"$WTW $WW - SA author runs circles around Wall Street on Weight Watchers https://seekingalpha.com/news/3232408-sa-author-runs-circles-around-wall-street-on-weight-watchers?source=tweet\" data-url=\"https://seekingalpha.com/news/3232408-sa-author-runs-circles-around-wall-street-on-weight-watchers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232400\" data-ts=\"1482502813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPR\" target=\"_blank\">TPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232400-coach-and-kate-spade-look-for-breakouts-from-lows\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coach and Kate Spade look for breakouts from lows</a></h4><ul> <li>If there is a <a href=\"http://www.wsj.com/articles/designer-stuart-vevers-is-transforming-coach-into-a-fashion-house-1482411603\" target=\"_blank\">turnaround</a> at Coach (COH) it could be due in part to the work of British designer Stuart Vevers.</li> <li>Vevers has been successful at rebranding Coach, according to W editor Stefano Tonchi. \"You say Coach today and you identify not just with a bag, but with a wardrobe,\" he notes.</li> <li>Trader Marc Lehman <a href=\"https://twitter.com/markflowchatter/status/812295431241789444\" target=\"_blank\">hypothesizes</a> that Coach may consider buying Kate Spade (NYSE:<a href=\"https://seekingalpha.com/symbol/KATE\" title=\"Kate Spade &amp; Company\">KATE</a>). It's interesting timing with Kate closing at a multi-year low of $14.02 yesterday. Kate Spade has been on the wrong side of the Trump trade due to concerns over import and sourcing policies.</li>\n<li>KATE is <font color=\"green\">up 1.78%</font> in premarket action and COH is <font color=\"green\">2.19% higher</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3232400\" data-linked=\"Coach and Kate Spade look for breakouts from lows\" data-tweet=\"$TPR $TPR $KATE - Coach and Kate Spade look for breakouts from lows https://seekingalpha.com/news/3232400-coach-and-kate-spade-look-for-breakouts-from-lows?source=tweet\" data-url=\"https://seekingalpha.com/news/3232400-coach-and-kate-spade-look-for-breakouts-from-lows\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232399\" data-ts=\"1482502674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232399-analysts-split-on-sarepta-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts split on Sarepta; shares up 2% premarket</a></h4><ul>\n<li>As followers of Sarepta Therapeutics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SRPT\" title=\"Sarepta Therapeutics, Inc.\">SRPT</a>) know, there is a wide variety of views about its valuation and efficacy/market potential for DMD drug Exondys 51 (eteplirsen). <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/12/8835833/2-opposing-views-on-the-future-of-sarepta\" target=\"_blank\">Sell-side analysts</a>, for example have fair valuation targets ranging from $32 - 106.</li>\n<li>Leerink's Joseph Schwartz rates the stock Market Perform with a $33 (17% upside) price target, down from $55. He says the company has yet to announce the launch metrics it will use (due next month) but he expects the company to fall short of expectations, especially considering that consensus estimates imply that Exondys 51 will be one of the biggest orphan drug launches in history. He adds that payers have indicated a \"wide range of reimbursement behavior\" from outright denials to more accommodative positions.</li>\n<li>JPMorgan's group rates it Overweight with a $40 (42% upside) price target despite negative sentiment on the company's business and mixed feedback from payers. They expect the stock to be range-bound in H1 2017 with a possible rally thereafter once market dynamics are better known.</li>\n<li>Shares are up <font color=\"green\">2%</font> premarket on light volume.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232399\" data-linked=\"Analysts split on Sarepta; shares up 2% premarket\" data-tweet=\"$SRPT - Analysts split on Sarepta; shares up 2% premarket https://seekingalpha.com/news/3232399-analysts-split-on-sarepta-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3232399-analysts-split-on-sarepta-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232397\" data-ts=\"1482502517\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232397-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/DPRX\" title=\"Dipexium Pharmaceuticals, LLC\">DPRX</a> <font color=\"green\">+66%</font>. <a href=\"https://seekingalpha.com/symbol/CNAT\" title=\"Conatus Pharmaceuticals\">CNAT</a> <font color=\"green\">+7%</font>. URRE <font color=\"green\">+7%</font>. <a href=\"https://seekingalpha.com/symbol/FRED\" title=\"Fred's, Inc.\">FRED</a> <font color=\"green\">+7%</font>.</li> <li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/BCEI\" title=\"Bonanza Creek Energy\">BCEI</a> <font color=\"red\">-41%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3232397\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$DPRX $CNAT $WWR - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3232397-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3232397-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232396\" data-ts=\"1482501708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALV\" target=\"_blank\">ALV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232396-autoliv-retreats-after-recall-disclosed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Autoliv retreats after recall disclosed</a></h4><ul> <li>Autoliv (NYSE:<a href=\"https://seekingalpha.com/symbol/ALV\" title=\"Autoliv Inc.\">ALV</a>) slumps in early trading after the <a href=\"https://www.nhtsa.gov/\" target=\"_blank\">NHTSA</a> said the company is recalling as many as 266,797 seat bealt retractors.</li> <li>114K seat belt and air bag inflators are also being recalled.</li> <li>ALV <font color=\"red\">-2.12%</font> premarket to $109.17 vs. a 52-week trading range of $93.31 to $127.74.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3232396\" data-linked=\"Autoliv retreats after recall disclosed\" data-tweet=\"$ALV - Autoliv retreats after recall disclosed https://seekingalpha.com/news/3232396-autoliv-retreats-after-recall-disclosed?source=tweet\" data-url=\"https://seekingalpha.com/news/3232396-autoliv-retreats-after-recall-disclosed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232393\" data-ts=\"1482501306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVFM\" target=\"_blank\">EVFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232393-neothetics-initiates-mid-stage-study-of-lead-product-candidate-for-reduce-double-chin-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neothetics initiates mid-stage study of lead product candidate for reduce double chin; shares ahead 21% premarket</a></h4><ul>\n<li>Thinly traded nano cap Neothetics (NEOT) is up <font color=\"green\">21%</font> premarket, albeit on only 430 shares, in response to the initiation of a Phase 2 clinical trial, LIPO-202-CL-31, evaluating lead product candidate LIPO-202 for the reduction of submental subcutaneous fat (fat under the chin).</li>\n<li>The 150-subject study will assess two doses of LIPO-202 compared to placebo for reducing submental bulging due to subcutaneous fat. Participants will receive up to 30 subcutaneous injections of LIPO-202 or placebo once per week for eight weeks. Top-line data should be available in late Q2 2017.</li>\n<li>\n<a href=\"http://www.neothetics.com/lipo.html\" target=\"_blank\">LIPO-202</a> is an injectable formulation of salmeterol xinafoate, a well-known long-acting beta2-adrenergic receptor agonist used in several commercially available inhaled drugs, including GlaxoSmithKline's (NYSE:<a href=\"https://seekingalpha.com/symbol/GSK\" title=\"GlaxoSmithKline\">GSK</a>) SEREVENT DISKUS. Earlier studies suggested that salmeterol xinafoate activates beta2-adrenergic receptors in fat cells, triggering the metabolism of triglycerides and shrinking them via a process called lipolysis.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232393\" data-linked=\"Neothetics initiates mid-stage study of lead product candidate for reduce double chin; shares ahead 21% premarket\" data-tweet=\"$EVFM $EVFM $GSK - Neothetics initiates mid-stage study of lead product candidate for reduce double chin; shares ahead 21% premarket https://seekingalpha.com/news/3232393-neothetics-initiates-mid-stage-study-of-lead-product-candidate-for-reduce-double-chin-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3232393-neothetics-initiates-mid-stage-study-of-lead-product-candidate-for-reduce-double-chin-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232390\" data-ts=\"1482500837\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232390-loonieminus-0_4-after-soft-canada-gdp-print\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loonie -0.4% after soft Canada GDP print</a></h4><ul>\n<li>\n<a href=\"http://www.statcan.gc.ca/daily-quotidien/161223/dq161223a-eng.htm?HPA=1\" target=\"_blank\">Canadian GDP contracted</a> 0.3% in October vs. expectations for a flat read. GDP had previously risen for four straight months, including 0.4% growth in September.</li>\n<li>We're almost in January, so this is pretty old news, but it's nevertheless an excuse for some to lighten up on the loonie (NYSEARCA:<a href=\"https://seekingalpha.com/symbol/FXC\" title=\"CurrencyShares Canadian Dollar Trust ETF\">FXC</a>), now <font color=\"red\">down 0.4%</font> vs. the greenback at $0.7384.</li>\n<li>ETFs: <a href=\"https://seekingalpha.com/symbol/EWC\" title=\"iShares MSCI Canada ETF\">EWC</a>, <a href=\"https://seekingalpha.com/symbol/CNDA\" title=\"IQ Canada Small Cap ETF\">CNDA</a>, <a href=\"https://seekingalpha.com/symbol/EWCS\" title=\"iShares MSCI Canada Small Cap Index ETF\">EWCS</a>, <a href=\"https://seekingalpha.com/symbol/FCAN\" title=\"First Trust Canada AlphaDex ETF\">FCAN</a>, <a href=\"https://seekingalpha.com/symbol/QCAN\" title=\"SPDR MSCI Canada Quality Mix ETF\">QCAN</a>, <a href=\"https://seekingalpha.com/symbol/HEWC\" title=\"iShares Currency Hedged MSCI Canada ETF\">HEWC</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232390\" data-linked=\"Loonie -0.4% after soft Canada GDP print\" data-tweet=\"$FXC $EWC $CNDA - Loonie -0.4% after soft Canada GDP print https://seekingalpha.com/news/3232390-loonieminus-0_4-after-soft-canada-gdp-print?source=tweet\" data-url=\"https://seekingalpha.com/news/3232390-loonieminus-0_4-after-soft-canada-gdp-print\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232387\" data-ts=\"1482499725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LMT\" target=\"_blank\">LMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232387-lockheed-martin-down-2-on-trump-tweet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lockheed Martin down 2% on Trump tweet</a></h4><ul>\n<li>\n<a href=\"https://twitter.com/realDonaldTrump/status/812061677160202240\" target=\"_blank\">From about 5 ET</a> yesterday evening ...</li>\n<li>\"Based on the tremendous cost and cost overruns of the Lockheed Martin F-35, I have asked Boeing to price-out a comparable F-18 Super Horne!\"</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/LMT\" title=\"Lockheed Martin\">LMT</a> <font color=\"red\">-2%</font> premarket</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232387\" data-linked=\"Lockheed Martin down 2% on Trump tweet\" data-tweet=\"$LMT - Lockheed Martin down 2% on Trump tweet https://seekingalpha.com/news/3232387-lockheed-martin-down-2-on-trump-tweet?source=tweet\" data-url=\"https://seekingalpha.com/news/3232387-lockheed-martin-down-2-on-trump-tweet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232385\" data-ts=\"1482499400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232385-new-age-beverages-files-for-new-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages files for new share offering</a></h4><ul> <li>New Age Beverages Corp (NASDAQ:<a href=\"https://seekingalpha.com/symbol/NBEV\" title=\"New Age Beverages Corporation\">NBEV</a>) moves up sharply after the company files for a new public offering of shares.</li> <li>The company says it expects an uplisting to the Nasdaq.</li> <li>NBEV <font color=\"green\">+14.22%</font> premarket to $5.14.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232385\" data-linked=\"New Age Beverages files for new share offering\" data-tweet=\"$NBEV - New Age Beverages files for new share offering https://seekingalpha.com/news/3232385-new-age-beverages-files-for-new-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3232385-new-age-beverages-files-for-new-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232380\" data-ts=\"1482498368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232380-aegis-sees-upside-for-fedex-ups\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aegis sees more upside for FedEx than UPS</a></h4><ul> <li>Aegis initiates coverage on FedEx (NYSE:<a href=\"https://seekingalpha.com/symbol/FDX\" title=\"FedEx Corporation\">FDX</a>) at Buy and on UPS (NYSE:<a href=\"https://seekingalpha.com/symbol/UPS\" title=\"United Parcel Service, Inc.\">UPS</a>) with a Hold.</li> <li>FedEx scores a price target of $215 (13% upside) from the investment firm, while the PT on UPS is $120 (+3% upside).</li> <li>FDX <font color=\"green\">+1.11%</font> premarket to $193.00. UPS <font color=\"green\">+0.13%</font> to $116.45.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3232380\" data-linked=\"Aegis sees more upside for FedEx than UPS\" data-tweet=\"$FDX $FDX $UPS - Aegis sees more upside for FedEx than UPS https://seekingalpha.com/news/3232380-aegis-sees-upside-for-fedex-ups?source=tweet\" data-url=\"https://seekingalpha.com/news/3232380-aegis-sees-upside-for-fedex-ups\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232368\" data-ts=\"1482497144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AERI\" target=\"_blank\">AERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232368-aerie-pharmaceuticals-updates-timing-of-nda-filing-for-rhopressatm-0_02-shares-off-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aerie Pharmaceuticals updates timing of NDA filing for Rhopressatm 0.02%; shares off 6% premarket</a></h4><ul> <li>Aerie Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AERI\" title=\"Aerie Pharmaceuticals, Inc.\">AERI</a>) reports that the manufacturing       line related to <a href=\"http://aeriepharma.com/products-at-a-glance/#Rhopressa\" target=\"_blank\">Rhopressa</a> in their Tampa, Florida facility       will not be ready for pre-approval inspection by the FDA until the end       of February 2017.</li>\n<li>In October 2016, the Rhopressa NDA (New       Drug Application) was withdrawn due to the third party contract manufacturer not being prepared for pre-approval inspection by the FDA. Aerie now expects to resubmit the Rhopressa NDA filing near       the end of Q1 2017.</li>               <li>Rhopressa (netarsudil ophthalmic solution) 0.02%, is a       novel eye drop that if approved, would become the only       once-daily product available that specifically targets the trabecular meshwork, the eye\u2019s primary fluid       drain and the diseased tissue responsible for elevated intraocular       pressure (IOP) in glaucoma.</li>\n<li>Shares are down <font color=\"red\">6%</font> premarket but only on 35 shares.</li>               </ul><div class=\"tiny-share-widget\" data-id=\"3232368\" data-linked=\"Aerie Pharmaceuticals updates timing of NDA filing for Rhopressatm 0.02%; shares off 6% premarket\" data-tweet=\"$AERI - Aerie Pharmaceuticals updates timing of NDA filing for Rhopressatm 0.02%; shares off 6% premarket https://seekingalpha.com/news/3232368-aerie-pharmaceuticals-updates-timing-of-nda-filing-for-rhopressatm-0_02-shares-off-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3232368-aerie-pharmaceuticals-updates-timing-of-nda-filing-for-rhopressatm-0_02-shares-off-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":39,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}